Author(s):
Vidya R. Mhatre, Ashish S. Jain, Mukesh S. Patil, Shrikant V Joshi, Vilas Surana, Sanika M. Kawade, Anushka D. Patil, Siddh A. Chaudhari, Om S. Lohar, Sakshi S. Sangle
Email(s):
vidyamhatre1501@gmail.com
DOI:
10.52711/2231-5675.2026.00022 
Address:
Vidya R. Mhatre1, Ashish S. Jain*1, Mukesh S. Patil1, Shrikant V Joshi2, Vilas Surana2, Sanika M. Kawade1, Anushka D. Patil1, Siddh A. Chaudhari1, Om S. Lohar1 , Sakshi S. Sangle1
1Department of Quality Assurance, Shri. D.D. Vispute College of Pharmacy and Research Center, Devad-Vichumbe, Panvel - 410221, Maharashtra, India.
2Maliba Pharmacy College, Bardoli, Mahuva Road, Tarsadi , Dist: Surat - 394 350, Gujarat, India
*Corresponding Author
Published In:
Volume - 16,
Issue - 2,
Year - 2026
ABSTRACT:
Forced degradation studies are a fundamental requirement in pharmaceutical development for establishing stability-indicating analytical methods and ensuring drug product quality throughout its lifecycle. By exposing active pharmaceutical ingredients and formulations to controlled stress conditions such as hydrolytic, oxidative, thermal, photolytic, and humidity stress, forced degradation enables the identification of degradation pathways, characterization of degradation products, and assessment of intrinsic molecular stability. This comprehensive review critically examines the role of forced degradation in stability-indicating method development, with emphasis on regulatory expectations outlined by ICH, FDA, and EMA. Key factors affecting drug stability, types of stability testing, stress study design, analytical techniques for degradation profiling, and method validation parameters are systematically discussed. The review highlights how forced degradation data support impurity qualification, formulation and packaging decisions, shelf-life estimation, and risk-based quality management. Overall, forced degradation studies serve as a cornerstone in assuring pharmaceutical product safety, efficacy, and regulatory compliance.
Cite this article:
Vidya R. Mhatre, Ashish S. Jain, Mukesh S. Patil, Shrikant V Joshi, Vilas Surana, Sanika M. Kawade, Anushka D. Patil, Siddh A. Chaudhari, Om S. Lohar, Sakshi S. Sangle. Asian Journal of Pharmaceutical Analysis. 2026; 16(2):145-2. doi: 10.52711/2231-5675.2026.00022
Cite(Electronic):
Vidya R. Mhatre, Ashish S. Jain, Mukesh S. Patil, Shrikant V Joshi, Vilas Surana, Sanika M. Kawade, Anushka D. Patil, Siddh A. Chaudhari, Om S. Lohar, Sakshi S. Sangle. Asian Journal of Pharmaceutical Analysis. 2026; 16(2):145-2. doi: 10.52711/2231-5675.2026.00022 Available on: https://ajpaonline.com/AbstractView.aspx?PID=2026-16-2-12
REFERENCES:
1. Venkatesh DN. Forced degradation – a review. Biomed J Sci Tech Res. 2022; 47(3).
2. Husain A. Forced degradation studies. J Anal Pharm Res. 2016; 3(6).
3. U.S. Food and Drug Administration. Guidance for industry: Q1A(R) stability testing of new drug substances and products. Rockville (MD): CDER, DHHS; 2003. p. 22–28.
4. International Conference on Harmonisation (ICH). Impurities in new drug products Q3B. Geneva: IFPMA; 1996.
5. Zothanpuii F, et al. A review on stability testing guidelines of pharmaceutical products. Asian J Pharm Clin Res. 2020; 13(10): 3–9.
6. Thorat P, et al. Stability study of dosage form: An innovative step. World J Pharm Pharm Sci. 2014; 3: 1031–1050.
7. Khushbu M, et al. Development of forced degradation and stability-indicating studies for drug substance and drug product. Int J Res Pharmacol Pharmacother. 2016; 5(4): 291–297.
8. Bhaskar R, et al. Current trend in performance of forced degradation studies for drug substance and drug products. J Drug Deliv Ther. 2020;10(2-S):149–155.
9. Phadtare S, et al. A review on stability testing guidelines of pharmaceutical products (with case studies). Int J Pharm Res Appl. 2024; 9: 1258.
10. El-Malla SF, et al. Development of a stability-indicating HPLC method for determination of cenobamate: Study of basic degradation kinetics. BMC Chem. 2024; 18(1).
11. Sharma MK, Murugesan M. Forced degradation study: An essential approach to develop stability-indicating method. J Chromatogr Sep Tech. 2017; 8(1).
12. Shinde N. Pharmaceutical forced degradation studies with regulatory consideration. Pharm Methods. 2013; 3(4): 178–188.
13. FDA perspectives: Scientific considerations of forced degradation studies in ANDA submissions. PharmTech. 2012; 36.
14. Sule S, et al. Forced degradation in pharmaceuticals – a regulatory update. J Pharm Regul Affairs. 2024; 13(2): 42–48.
15. Marín A, Barbas C. LC–MS for degradation profiling of cough–cold products under forced conditions. J Pharm Biomed Anal. 2004; 35(5): 1035–1045.
16. Bakshi M, Singh S. Development of validated stability-indicating assay methods: A critical review. J Pharm Biomed Anal. 2002; 28: 1011–1040.
17. Tollefson AE, et al. Forced degradation of FAST inhibits apoptosis in adenovirus-infected cells. Nature. 1998; 392:726–730.
18. Bajaj S, et al. Stability testing of pharmaceutical products. J Appl Pharm Sci. 2021; 2(3).
19. International Conference on Harmonisation (ICH). Q1A(R2): Stability testing of new drug substances and products. Geneva: ICH; 2003.
20. Panda A, et al. Stability studies: An integral part of drug development process. Int J Pharm Res Bio Sci. 2013; 2(6): 69–80.
21. Sultana S, Mohammed S. A review on stability studies of pharmaceutical products. Int J Pharm Res Scholars. 2018; 7(1): 28–49.
22. Pokharana M, et al. Stability testing guidelines of pharmaceutical products. J Drug Deliv Ther. 2018; 8(2).
23. Aashigari S, et al. Stability considerations in pharmaceutical products. World J Pharm Res. 2019; 8.
24. Florence AT, Siepmann J, editors. Modern pharmaceutics. Vol. 1. Boca Raton (FL): CRC Press; 2009. p. 219–245.
25. Kaur M, et al. Stability and degradation studies of pharmaceutical dosage forms. Int J Pharm Chem Biol Sci.
26. Zothanpuii F, et al. A review on stability testing guidelines of pharmaceutical products. Int J Pharm Chem Biol Sci. 2020;13(10):1–10.
27. Kommanaboyina B, Rhodes CT. Trends in stability testing with emphasis on distribution and storage. Drug Dev Ind Pharm. 1999; 25(7): 857–868.
28. International Council for Harmonisation (ICH). Q2(R2): Validation of analytical procedures. Geneva: ICH.
29. Admin. Forced degradation study – a new approach for stress testing of drug substances and drug products. Int J Pharm Sci Res.
30. Zaman B, et al. Forced degradation studies and development of HPLC-UV method for velpatasvir solid dispersion. Antibiotics. 2022; 11(7): 897.
31. Liu W, et al. Optimal methods for quenching hydrogen peroxide residuals. Water Res. 2003; 37(15): 3697–3703.
32. Keen OS, et al. Evaluation of hydrogen peroxide chemical quenching agents. J Environ Eng. 2013; 139(1): 137–140.
33. International Conference on Harmonisation (ICH). Q3B(R2): Impurities in new drug products. Geneva: ICH; 2006.
34. Rakibe U, et al. LC and LC–MS/MS studies of degradation products of acebutolol. J Pharm Anal. 2018; 8(6): 357–365.
35. Alanazi S. Recent advances in LC–MS applications. Anal Sci Adv. 2025; 6(1).
36. Gathungu RM, et al. Integration of LC–MS and NMR for trace analyte analysis. Mass Spectrom Rev. 2018; 39(1–2): 35–54.
37. Kaushal G, et al. LC-MS-based stability-indicating method for lonidamine. Res Pharm Sci. 2020; 15(4): 312.
38. Tamizi E, et al. Stability-indicating capillary electrophoresis method for buserelin. Iran J Pharm Res. 2025; 13(3): 797.
39. Chen D, et al. Recent advances in CE-MS for proteomics. Mass Spectrom Rev. 2021.
40. Kranenburg RF, et al. Benefits of derivatization in GC–MS identification. Forensic Chem. 2020; 20: 100273.
41. Biale G, et al. Degradation products from artificially aged microplastics. Polymers. 2021; 13(12): 1997.
42. de Alvarenga Junior R, et al. Chemometric approaches in forced degradation studies. Molecules. 2019; 24(20): 3804.
43. Bos TS, et al. Applications of chemometrics in chromatography. J Sep Sci. 2020; 43(9–10): 1678–1727.
44. Kumari KS, Bandhakavi S. Stability-indicating RP-HPLC method for ertugliflozin and metformin. Future J Pharm Sci. 2020; 6(1).
45. Musmade BD, et al. Impurity profiling of metformin and teneligliptin by RP-HPLC. Future J Pharm Sci. 2021; 7(1).
46. Bhujbal SV, et al. Pharmaceutical amorphous solid dispersions: A review. Adv Drug Deliv Rev. 2021; 177: 113911.
47. Tambe S, et al. Recent advances in amorphous solid dispersions. Int J Pharm. 2022; 622: 121811.
48. Baghel S, et al. Polymeric amorphous solid dispersions. J Pharm Sci. 2016; 105(9): 2527–2544.
49. Vasconcelos T, et al. Rational selection of manufacturing process for amorphous solid dispersions. Adv Drug Deliv Rev. 2016; 100: 85–101.
50. Kotha RR, et al. Oxidative degradation in pharmaceuticals. J Pharm Biomed Anal. 2022; 220: 114962.
51. Qiu Y, et al. Developing solid oral dosage forms. Cambridge (MA): Academic Press; 2016.
52. Allen PV, Baertschi SW. Stability considerations for amorphous pharmaceuticals. Pharm Dev Technol. 2019; 24(9): 1037–1042.
53. Mah P, et al. Stabilization strategies for amorphous solid dispersions. Mol Pharm. 2022; 19(5): 1459–1477.
54. Jelić D. Thermal stability of amorphous solid dispersions. Molecules. 2021; 26(1): 238.
55. Schittny A, et al. Mechanisms of increased bioavailability through amorphous solid dispersions. Drug Dev Ind Pharm. 2020; 46(3): 421–432.
56. Rao TN, Hussain I, Prashanthi Y, Patrudu TB. Forced degradation study for tolterodine by HPLC with PDA detection. Asian J Pharm Anal. 2019; 9(2): 77–81.
57. Chalikwar SS, Moravakar KK, Bhairav BA. Stability-indicating method development and validation for estimation of valacyclovir in pharmaceutical preparation. Asian J Pharm Anal. 2024; 14(2): 53–59.
58. Thangabalan B, Koya A, Chaitanya G, Sunitha N, Babu SM. Stability-indicating RP-HPLC method for the estimation of acamprosate in pure and tablet dosage form. Asian J Pharm Anal. 2013;3(4):141–146.
59. Daharwal SJ. Development and validation of UV spectrophotometric method for simultaneous estimation of diazepam and propranolol in bulk drug and its formulations. Asian J Pharm Anal. 2013; 3(1): 20–23.
60. Kathirvel S, Raju R, Seethadevi B, Suneetha A, Jyothisree K. Liquid chromatographic method for the determination of content uniformity of tetrabenazine. Asian J Pharm Anal. 2015; 5(2): 86–92.
61. Housheh S, Trefi S, Chehna MF. Identification and characterization of prasugrel degradation products by GC/MS, FTIR and 1H NMR. Asian J Pharm Anal. 2017; 7(2): 55–66.
62. Khan H, Ali J. Identification of impurities and degradation products in pharmaceutical products: Role of hyphenated techniques. Asian J Pharm Anal. 2017; 7(1): 31–35.
63. Vyas AJ, Gol DA, Patel AI, Patel AB, Patel NK, Chudasama A. A stress degradation kinetic study of tadalafil bulk and tablet dosage form by UV spectrophotometry. Asian J Pharm Anal. 2020; 10(4): 177–181.
64. Sutar PS, Munde MK, Vichare VS, Kulkarni NS. Review on forced degradation study of statins. Asian J Pharm Anal. 2022; 12(2): 135–141.
65. Khaire RD, Pawar PY. A review on development of stability-indicating analytical methods for drugs in bulk and pharmaceutical dosage form. Asian J Pharm Anal. 2022; 12(4): 261–263.
66. Vyas AJ, Jadav CD, Patel AI, Patel AB, Shah SR, Sheth D, Dholakia S. Review on stability-indicating assay method or forced degradation study: Strategy and regulatory consideration. Asian J Pharm Anal. 2023; 13(2): 131–139.